Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2020

01-12-2020 | Lung Cancer | Case Report

A first case report of clinical response to targeted therapy in a patient with primary myoepithelial carcinoma of the lung harboring EGFR exon 19 deletion

Authors: Xiaohong Xie, Xinqing Lin, Ming Liu, Yinyin Qin, Ming Ouyang, Shiyue Li, Yingying Gu, Shuyin Chen, Jianxing Xiang, Chengzhi Zhou

Published in: Diagnostic Pathology | Issue 1/2020

Login to get access

Abstract

Background

Primary myoepithelial carcinoma of the lung is a rare subtype in lung cancer. Comprehensive molecular profiling of myoepithelial carcinoma of the lung is absent, neither was clinical evidence of targeted therapy available for this disease. Therefore, the optimal treatment regimen of this tumor needs to be established.

Case presentation

Here we present a case of a 68-year-old patient with stage IVB primary myoepithelial carcinoma of the lung who harbored EGFR exon 19 deletion and KRAS mutation and underwent icotinib targeted therapy, achieving partial response (PR) with progression free survival (PFS) of 3 months.

Conclusion

To our knowledge, this study describes the first documented case of primary myoepithelial carcinoma lung cancer patient harboring EGFR exon 19 deletion and KRAS mutation, and showed clinical efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) treatment in this patient.
Literature
1.
Song DH, Choi IH, Ha SY, et al. Epithelial-myoepthelial carcinoma of the tracheobronchial tree: the prognostic role of myoepithelial cells. Lung Cancer. 2014;83(3):416–9.CrossRef
2.
Dardick I. Myoepithelioma: definitions and diagnostic criteria. Ultrastruct Pathol. 1995;19(5):335–45.CrossRef
3.
Savera AT, Sloman A, Huvos AG, Klimstra DS. Myoepithelial carcinoma of the salivary glands: a clinicopathologic study of 25 patients. Am J Surg Pathol. 2000;24(6):761–74.CrossRef
4.
Dhawan A, Shenoy A, Sriprakash D. Myoepithelial carcinoma of the nasopharynx: case report of a rare entity. Natl J Maxillofac Surg. 2011;2(2):207–9.CrossRef
5.
Noronha V, Cooper DL, Higgins SA, Murren JR, Kluger HM. Metastatic myoepithelial carcinoma of the vulva treated with carboplatin and paclitaxel. Lancet Oncol. 2006;7(3):270–1.CrossRef
6.
Jo VY, Fletcher CD. Myoepithelial neoplasms of soft tissue: an updated review of the clinicopathologic, immunophenotypic, and genetic features. Head Neck Pathol. 2015;9(1):32–8.CrossRef
7.
Chamberlain F, Cojocaru E, Scaranti M, et al. Adult soft tissue myoepithelial carcinoma: treatment outcomes and efficacy of chemotherapy. Med Oncol. 2019;37(2):13.CrossRef
8.
Miura K, Harada H, Aiba S, Tsutsui Y. Myoepithelial carcinoma of the lung arising from bronchial submucosa. Am J Surg Pathol. 2000;24(9):1300–4.CrossRef
9.
Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008;9(10):962–72.CrossRef
10.
Ludovini V, Bianconi F, Pistola L, et al. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011;6(4):707–15.CrossRef
11.
Wang Z, Cheng Y, An T, et al. Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial. Lancet Respir Med. 2018;6(9):681–90.CrossRef
12.
Fiala O, Pesek M, Finek J, Benesova L, Belsanova B, Minarik M. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Cancer Genet. 2013;206(1–2):26–31.CrossRef
Metadata
Title
A first case report of clinical response to targeted therapy in a patient with primary myoepithelial carcinoma of the lung harboring EGFR exon 19 deletion
Authors
Xiaohong Xie
Xinqing Lin
Ming Liu
Yinyin Qin
Ming Ouyang
Shiyue Li
Yingying Gu
Shuyin Chen
Jianxing Xiang
Chengzhi Zhou
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2020
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/s13000-020-00986-0

Other articles of this Issue 1/2020

Diagnostic Pathology 1/2020 Go to the issue

Case Report

Cutaneous T-cell lymphomas with pathogenic somatic mutations and absence of detectable clonal T-cell receptor gene rearrangement: two case reports

Research

Fine needle biopsy of malignant tumors of the liver: a retrospective study of 624 cases from a single institution experience

Research

Ovarian mucinous tumors with mural nodules: immunohistochemical and molecular analysis of 3 cases

Research

Circ_0001421 facilitates glycolysis and lung cancer development by regulating miR-4677-3p/CDCA3

Case Report

Genetic profiling of patients with adenoid cystic carcinoma of the Bartholin’s glands reveals potential new routes for targeted therapies: a case report

Research

Diagnostic value of clusterin immunostaining in hepatocellular carcinoma